Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Fifteen analysts give ABVX an average rating of "Moderate Buy" (13 buy, 1 sell, 1 strong buy) with a mean 12‑month price target of about $137.15.
• Financial/market snapshot: ABVX opened at $113 with a one‑year range of $5.59–$148.83 and a market cap of $8.96B, but it reported a quarterly EPS of −$1.20 on just $0.52M revenue and analysts forecast −3.84 EPS for the year, highlighting significant financial and clinical risk.
• Company profile and investor interest: Abivax is a Paris‑based clinical‑stage biopharma developing obefazimod (ABX464) for inflammatory diseases, and institutional investors own about 47.91% of the stock amid recent hedge‑fund buying activity.

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) have been given an average rating of "Moderate Buy" by the fifteen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $137.1538.

A number of research analysts have recently weighed in on ABVX shares. Jefferies Financial Group started coverage on Abivax in a report on Monday, March 16th. They issued a "buy" rating and a $160.00 price objective on the stock. Barclays increased their price objective on Abivax from $142.00 to $148.00 and gave the company an "overweight" rating in a report on Tuesday, March 24th. Oddo Bhf reissued an "outperform" rating on shares of Abivax in a report on Thursday, April 9th. Oppenheimer set a $131.00 price objective on Abivax in a report on Thursday, January 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Abivax in a report on Monday.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ABVX. GHP Investment Advisors Inc. increased its holdings in shares of Abivax by 155.6% in the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company's stock valued at $26,000 after purchasing an additional 140 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock worth $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Abivax in the third quarter worth about $36,000. Bank of America Corp DE boosted its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Finally, Hantz Financial Services Inc. purchased a new stake in shares of Abivax in the third quarter worth about $52,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of ABVX opened at $113.00 on Friday. The stock has a 50-day moving average of $118.48 and a two-hundred day moving average of $115.50. Abivax has a one year low of $5.59 and a one year high of $148.83. The stock has a market cap of $8.96 billion, a P/E ratio of -21.04 and a beta of 1.68.

Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The firm had revenue of $0.52 million during the quarter. Analysts predict that Abivax will post -3.84 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.